On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and ...
On Wednesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $110.42 which represents a decrease of $-1.11 or -1.00% from the prior close of $111.53. The stock opened at $111 and touched ...